Biomarkers of efficacy and safety of the academic BCMA-CART ARI0002h for the treatment of refractory multiple myeloma.
Marta GarroteMarta Español-RegoAintzane ZabaletaVerónica González De La CalleSergio Navarro-VelázquezSusana I InogesAscensión López-Díaz de CerioValentín CabañasNieves López-MuñozPaula Rodriguez OteroJuan Luis RegueraDavid F MorenoNuria Martinez-CibrianLucía López CorralLorena Perez-AmillBeatriz Martin-AntonioLaura RosinolJoan CidNatalia TovarJoaquin Saez-PeñataroMiriam Lopez-ParraEulalia OlestiElena GuillenSara VareaLuis-Gerardo Rodríguez-LobatoAnthony Matthew BattramMarta Sonia GonzálezAndrés Sánchez-SalinasEuropa Azucena González-NavarroValentín Ortiz-MaldonadoJulio DelgadoFelipe ProsperManel JuanJoaquin Martinez LopezJosé María M MoraledaMaria-Victoria Mateos-MantecaAlvaro Urbano-IspizuaJuan José LahuertaMariona PascalCarlos Fernández de LarreaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Despite deep and sustained responses achieved with ARI0002h, we identified several biomarkers that correlate with poor outcomes.